Rajiv Kaul hunts for the next big thing in biotech. As manager of the nearly identical Fidelity Select Biotechnology (symbol FBIOX) and Fidelity Advisor Biotechnology (FBTAX) funds, he attends conferences, talks up experts and studies data to find biotech companies with promising drugs.
Once he identifies a potential investment, Kaul tries to predict how successful a drug could be. To measure that, he seeks to determine how many people would take it, how many doctors would prescribe it and what the competitive landscape looks like. Kaul tends to avoid companies with drugs in early-stage testing because there's too much uncertainty about a product's success. "I'd rather wait until the drug gets approved or we have data that shows it works," says Kaul, who has managed both of the biotech funds since October 2005.
That said, both funds hold speculative biotech firms as well as established, profitable outfits. At last report, Select Biotech's three biggest holdings were Gilead Sciences, Biogen Idec and Celgene (all profitable and accounting for 23% of Select's assets). A hefty one-fourth of the fund's assets are in so-called microcaps (companies with market values of $300 million or less), including such money-losing obscurities as ArQule and PolyMedix. "I try to strike a balance between investing in firms that generate a steady stream of cash and those that offer a growing pipeline" of new products, says Kaul.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Once Kaul finds a potential winner, he estimates how much cash flow a company could generate from a drug over ten years. Using these projections, he determines a company's value. If a stock sells for less than his estimate, he buys.
Both funds follow the same strategy and have similar holdings, but they charge different fees. Select Biotech is sold directly to investors and will slap you with a 0.75% charge if you sell shares within 30 days of buying them. Advisor Biotech is only available through financial intermediaries and comes in a variety of share classes with different fee structures.
Over the past year through April 30, Select Biotech returned 19.6%, beating the average health-care fund by nearly 14 percentage points and Standard & Poor's 500-stock index by 15 points. Over the past five years, Select Biotech gained 8.9% annualized, topping the average health fund by an average of 4.0 points per year and the S&P 500 by 7.9 points a year. The Class A shares of Advisor Biotech returned 20.9% over the past year and 8.6% annualized over the past five.
As for biotech's future, the best is yet to come, in Kaul's view. "Science has greatly advanced over the past few years," he says. "We're at an inflection point where there will be a lot of innovation over the next ten years." He also thinks big drug makers will continue to snap up biotech companies to fill empty pipelines with new products.
Follow Jennifer on Twitter or become her fan on Facebook.
ORDER NOW: Buy Kiplinger’s Mutual Funds 2012 special issue for in-depth guidance on the only investments you need.
-
I'm want to give my 3 grandkids $5K each for Christmas.You're comfortably retired and want to give your grandkids a big Christmas check, but their parents are worried they might spend it all. We ask the pros for help.
-
If You're Not Doing Roth Conversions, You Need to Read ThisRoth conversions and other Roth strategies can be complex, but don't dismiss these tax planning tools outright. They could really work for you and your heirs.
-
Could Traditional Retirement Expectations Be Killing Us?A retirement psychologist makes the case: A fulfilling retirement begins with a blueprint for living, rather than simply the accumulation of a large nest egg.
-
The 5 Best Actively Managed Fidelity Funds to Buy and Holdmutual funds Sometimes it's best to leave the driving to the pros – and these actively managed Fidelity funds do just that, at low costs to boot.
-
The 12 Best Bear Market ETFs to Buy NowETFs Investors who are fearful about the more uncertainty in the new year can find plenty of protection among these bear market ETFs.
-
Don't Give Up on the Eurozonemutual funds As Europe’s economy (and stock markets) wobble, Janus Henderson European Focus Fund (HFETX) keeps its footing with a focus on large Europe-based multinationals.
-
Vanguard Global ESG Select Stock Profits from ESG Leadersmutual funds Vanguard Global ESG Select Stock (VEIGX) favors firms with high standards for their businesses.
-
Kip ETF 20: What's In, What's Out and WhyKip ETF 20 The broad market has taken a major hit so far in 2022, sparking some tactical changes to Kiplinger's lineup of the best low-cost ETFs.
-
ETFs Are Now Mainstream. Here's Why They're So Appealing.Investing for Income ETFs offer investors broad diversification to their portfolios and at low costs to boot.
-
Do You Have Gun Stocks in Your Funds?ESG Investors looking to make changes amid gun violence can easily divest from gun stocks ... though it's trickier if they own them through funds.
-
How to Choose a Mutual Fundmutual funds Investors wanting to build a portfolio will have no shortage of mutual funds at their disposal. And that's one of the biggest problems in choosing just one or two.
